Cartesian Growth Corporation III (CGCT) 股票分析
金融服务Cartesian Growth Corporation III
$10.85
+$0.99 (+10.04%)
最后更新: 2026年5月26日
价格走势
暂无价格数据
分析
公司概述
Cartesian Growth Corporation III is a shell company that does not engage in significant operational activities, instead focusing exclusively on effecting business combinations such as mergers, amalgamations, share exchanges, asset acquisitions, or reorganizations with one or more businesses or entities. The corporation operates within the Financial Services sector, specifically classified under the industry of Shell Companies, which typically implies a transitional status awaiting a strategic merger or acquisition to become an operating entity. The company's market capitalization stands at $354.32M, while its annual revenue is not disclosed as N/A, and the number of employees is also listed as N/A. This market cap figure indicates a substantial valuation relative to the typical small-cap shell companies that often have negligible asset bases, suggesting that the current price reflects market expectations regarding the probability and timing of a future merger rather than current operational cash flows.
财务健康
The company's financial statements report a Net Income (TTM) of $6.22M, whereas Revenue (TTM) and EBITDA are both recorded as N/A, creating a distinct scenario where profitability metrics are generated without corresponding revenue streams or traditional earnings before interest, taxes, debt, and amortization figures. This gap between the reported net income and the absence of revenue or EBITDA reveals a non-traditional cost structure where income is likely derived from transaction fees, warrants, or other financing arrangements associated with shell company activities rather than operational sales. The Free Cash Flow is reported at $-244,656, which indicates a consumption of cash reserves during the period, potentially due to transaction-related expenses or working capital adjustments, thereby limiting immediate financial flexibility for opportunistic acquisitions. Analysis of the three primary margins shows that Gross Margin, Operating Margin, and Profit Margin are all 0.0%, reflecting the fact that the company has no significant sales volume to generate operating leverage or gross profit on goods and services. On the balance sheet, the company holds Cash of $624,163 against zero Debt, while the Debt to Equity ratio is N/A, presenting a highly conservative capital structure devoid of leverage that would otherwise amplify financial risk. The Current Ratio stands at 0.89, indicating that current liabilities slightly exceed current assets, which suggests a potential liquidity constraint that must be addressed through future capital raises or merger proceeds. Return on Assets is -0.5%, and Return on Equity is N/A, metrics that reveal management has not yet generated positive returns on its asset base or equity capital, consistent with the transitional nature of a shell entity awaiting a business combination.
估值评估
The P/E Ratio (TTM) is 41.08, while the Forward P/E is N/A, implying that the market currently values the company based on historical earnings that may not be sustainable for a shell company lacking traditional revenue, and the absence of a forward P/E suggests analysts cannot project earnings growth with confidence until a target acquisition is identified. The Price to Book ratio is -26.81, a negative figure that indicates the market cap exceeds the book value in a manner that defies traditional valuation logic for operating firms, suggesting the market is pricing in the potential value of a future merger rather than the current net asset value. Neither the Price to Sales nor the EV/EBITDA ratios are available (N/A) because the company lacks the necessary revenue or EBITDA data, meaning these alternative valuation metrics cannot be calculated and offer no insight into the company's relative value compared to peers. The 52-Week High is $10.42 and the 52-Week Low is $10.00, and since the current trading price falls within this narrow range, the stock is trading at approximately 0% to 4% below the 52-week high, reflecting limited price volatility in the short term. The Beta value is N/A, which prevents a direct comparison of price volatility relative to the broader market, but the narrow trading range between the high and low suggests that the stock price is currently stable despite the lack of operational earnings to support such stability.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which means there is no historical data to compare against, and consequently, it is impossible to determine whether earnings are growing faster or slower than revenue given the company's transitional status. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that the corporation reinvests any available earnings or proceeds from financing activities into searching for a merger target rather than distributing income to shareholders. Since the dividend yield is not applicable, the payout ratio is inherently unsustainable in the traditional sense as there are no dividends paid, and the entire financial focus remains on capital preservation and strategic positioning for a business combination. The overall growth and income profile for Cartesian Growth Corporation III is currently non-existent in terms of operational expansion or shareholder distributions, as the entity is purely a vehicle designed to facilitate a future merger or acquisition that would fundamentally alter its growth trajectory and income generation capabilities.
同行比较
Cartesian Growth Corporation III (CGCT) 在壳公司行业运营。以下是其与市值最接近的同行的比较:
| 公司 | 代码 | 市值 | 市盈率 |
|---|---|---|---|
| Cartesian Growth Corporation III | CGCT | $449.19M | 36.2 |
| Twenty One Capital, Inc. | XXI | $2.49B | N/A |
| Churchill Capital Corp X | CCCX | $711.00M | N/A |
| Drugs Made In America Acquisition II Corp. | DMII | $641.46M | 77.5 |
壳公司行业平均市盈率为82.8倍。Cartesian Growth Corporation III的市盈率为36.2。
本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。
相关壳公司股票
Twenty One Capital, Inc.
$2.49B
CCCXChurchill Capital Corp X
$711.00M
DMIIDrugs Made In America Acquisition II Corp.
$641.46M
BCSSBain Capital GSS Investment Corp.
$595.68M
EVACEQV Ventures Acquisition Corp. II
$594.41M
CEPFCantor Equity Partners IV, Inc.
$591.50M
金融服务热门股票
Berkshire Hathaway Inc.
$1.38T
BRK-BBerkshire Hathaway Inc.
$1.04T
BRK-ABerkshire Hathaway Inc.
$1.04T
JPMJPMorgan Chase & Co.
$821.91B
VVisa Inc.
$620.88B
关于Cartesian Growth Corporation III
Cartesian Growth Corporation III does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. Cartesian Growth Corporation III was incorporated in 2024 and is based in New York, New York.
公司简介以英文显示。
访问官网 →